Triple-Modality Therapy May Improve Mesothelioma Outcomes, Study Suggests
A Canadian study suggests that triple-modality therapy with radiotherapy, immunotherapy, and surgery may extend the lives of people with malignant pleural mesothelioma. Pleural mesothelioma is an intractable cancer with a poor prognosis. It mainly affects people who have lived or worked around asbestos. There is no cure for mesothelioma. People who have the best mesothelioma outcomes usually have a combination of treatments. Now, scientists at Toronto General Hospital’s Research Institute say a triple-modality therapy they tested in mice might have the power to extend human lives, too. Multi-modal Mesothelioma Treatment Pleural mesothelioma is a fast-growing cancer that starts on the membrane around the lungs. Many mesothelioma patients die less than a year after diagnosis. There is no single accepted treatment…